Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 4 2Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1

Conditions

Breast Neoplasms 134Neoplasms 112Polycystic Ovary Syndrome 66Prostatic Neoplasms 63Colorectal Neoplasms 51Carcinoma, Non-Small-Cell Lung 46Pain 40Carcinoma, Hepatocellular 35Lung Neoplasms 34Keratosis, Actinic 32Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Neoplasm Metastasis 26Head and Neck Neoplasms 26Pain, Postoperative 25Stomach Neoplasms 24Colonic Neoplasms 23Multiple Myeloma 22Brain Neoplasms 21Pancreatic Neoplasms 20Lymphoma, Follicular 19Leukemia 19Anemia 19Uterine Cervical Neoplasms 18Leukemia, Myeloid, Acute 18Infertility 18Leiomyoma 17Lymphoma, Non-Hodgkin 16Lymphoma 16Cancer Pain 16Leukemia, Myelogenous, Chronic, BCR-ABL Positive 15

Interventions

Ultracet 1Morphine 1Gastrostomy 1Fentanyl 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Completed × Breakthrough Pain × Clear all
NCT02869321 2019-05-13

ANTALGIP

Central Hospital, Nancy, France

Phase 4 Completed
20 enrolled
Head & Neck

Head and Neck Neoplasms, Breakthrough Pain

NCT00576173 2010-04-28

An Open Label Study to Evaluate Safety, Tolerability and Clinical Utility of ULTRACET® (37.5mg Tramadol Hydrochloride/325mg Acetaminophen) for the Treatment of Breakthrough Pain in Cancer Patients

Johnson & Johnson Taiwan Ltd

Phase 4 Completed
60 enrolled

Cancer Pain, Pain, Breakthrough Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡